Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Parmiani

Showing results (171-180 of 301) with videos related to

Pageof 31
Sort By:
Methods in Molecular Medicine|February 11, 2012
Gene therapy in melanomaG Parmiani, F Arienti, C Melani, et al.
Melanoma Research|February 1, 1994
N-RAS mutations and susceptibility to lymphokine-activated killer (LAK) cells in human melanomaR Lupetti, M Sensi, R Mortarini, et al.
International Journal of Cancer|May 1, 1994
Cytotoxic T lymphocytes recognize tumor antigens of a murine colonic carcinoma by using different T-cell receptorsM Rodolfo, C Castelli, C Bassi, et al.
Cancer Research|January 1, 1986
Classes I and II HLA and melanoma-associated antigen expression and modulation on melanoma cells isolated from primary and metastatic lesionsD Taramelli, G Fossati, A Mazzocchi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 1, 1997
Mapping of HLA class I binding motifs in forty-four fusion proteins involved in human cancersC Gambacorti-Passerini, C Bertazzoli, S Dermime, et al.
Tumori|January 16, 1998
HLA binding characteristics and generation of cytotoxic lymphocytes against peptides derived from oncogenic proteinsC Bertazzoli, E Marchesi, S Dermime, et al.
The Journal of Clinical Investigation|June 24, 1998
beta2-Microglobulin mutations, HLA class I antigen loss, and tumor progression in melanomaD J Hicklin, Z Wang, F Arienti, et al.
Cancer Research|May 15, 1995
Down-regulation of interleukin 6 receptor alpha chain in interleukin 6 transduced melanoma cells causes selective resistance to interleukin 6 but not to oncostatin MA Silvani, G Ferrari, G Paonessa, et al.
Journal of Neurosurgical Sciences|July 1, 1990
Adoptive immunotherapy with adherent lymphokine-activated killer (A-LAK) cells in glioblastoma multiformeL Munari, A Silvani, C G Passerini, et al.
Journal of Immunological Methods|January 1, 1979
Preparation of antigenically active membranes from solid murine lymphomas and fibrosarcomasM A Pierotti, S Miotti, G D Torre, et al.
Pageof 31

Showing results (171-180 of 301) with videos related to

Sort By:
Pageof 31
Methods in Molecular Medicine|February 11, 2012
Gene therapy in melanomaG Parmiani, F Arienti, C Melani, et al.
Melanoma Research|February 1, 1994
N-RAS mutations and susceptibility to lymphokine-activated killer (LAK) cells in human melanomaR Lupetti, M Sensi, R Mortarini, et al.
International Journal of Cancer|May 1, 1994
Cytotoxic T lymphocytes recognize tumor antigens of a murine colonic carcinoma by using different T-cell receptorsM Rodolfo, C Castelli, C Bassi, et al.
Cancer Research|January 1, 1986
Classes I and II HLA and melanoma-associated antigen expression and modulation on melanoma cells isolated from primary and metastatic lesionsD Taramelli, G Fossati, A Mazzocchi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 1, 1997
Mapping of HLA class I binding motifs in forty-four fusion proteins involved in human cancersC Gambacorti-Passerini, C Bertazzoli, S Dermime, et al.
Tumori|January 16, 1998
HLA binding characteristics and generation of cytotoxic lymphocytes against peptides derived from oncogenic proteinsC Bertazzoli, E Marchesi, S Dermime, et al.
The Journal of Clinical Investigation|June 24, 1998
beta2-Microglobulin mutations, HLA class I antigen loss, and tumor progression in melanomaD J Hicklin, Z Wang, F Arienti, et al.
Cancer Research|May 15, 1995
Down-regulation of interleukin 6 receptor alpha chain in interleukin 6 transduced melanoma cells causes selective resistance to interleukin 6 but not to oncostatin MA Silvani, G Ferrari, G Paonessa, et al.
Journal of Neurosurgical Sciences|July 1, 1990
Adoptive immunotherapy with adherent lymphokine-activated killer (A-LAK) cells in glioblastoma multiformeL Munari, A Silvani, C G Passerini, et al.
Journal of Immunological Methods|January 1, 1979
Preparation of antigenically active membranes from solid murine lymphomas and fibrosarcomasM A Pierotti, S Miotti, G D Torre, et al.
Pageof 31